Biogened (BGD) 주식 개요바이오젠은 폴란드에서 의약품을 개발, 생산 및 유통하는 회사입니다. 자세히 보기BGD 펀더멘털 분석스노우플레이크 점수가치 평가4/6미래 성장0/6과거 실적2/6재무 건전성5/6배당3/6강점공정 가치 추정치보다 낮은 25% 에서 거래위험 분석지난 3개월 동안 주가 변동성이 Polish 시장과 비교했을 때 매우 높았습니다.의미 있는 시가총액이 없습니다(PLN46M)모든 위험 점검 보기BGD Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValuezłCurrent Pricezł18.6027.9% 저평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture0249m2016201920222025202620282031Revenue zł249.3mEarnings zł10.1mAdvancedSet Fair ValueView all narrativesBiogened S.A. 경쟁사Genomed Spólka AkcyjnaSymbol: WSE:GENMarket cap: zł31.7mRead-GeneSymbol: WSE:RDGMarket cap: zł59.7mOtsuka PakistanSymbol: KASE:OTSUMarket cap: PK₨3.4bBLIS TechnologiesSymbol: NZSE:BLTMarket cap: NZ$19.2m가격 이력 및 성과Biogened 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가zł18.6052주 최고가zł32.0052주 최저가zł17.30베타0.251개월 변동-5.58%3개월 변동-3.13%1년 변동-39.22%3년 변동32.86%5년 변동37.78%IPO 이후 변동-53.50%최근 뉴스 및 업데이트Buy Or Sell Opportunity • Apr 20Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 6.6% to zł19.80. The fair value is estimated to be zł24.82, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 13%.New Risk • Apr 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Market cap is less than US$100m (zł60.9m market cap, or US$17.0m).Valuation Update With 7 Day Price Move • Apr 15Investor sentiment improves as stock rises 39%After last week's 39% share price gain to zł24.80, the stock trades at a trailing P/E ratio of 13.2x. Average trailing P/E is 22x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 96% over the past three years.Reported Earnings • Feb 19Full year 2025 earnings released: EPS: zł1.88 (vs zł2.37 in FY 2024)Full year 2025 results: EPS: zł1.88 (down from zł2.37 in FY 2024). Revenue: zł114.0m (up 2.8% from FY 2024). Net income: zł4.62m (down 21% from FY 2024). Profit margin: 4.1% (down from 5.2% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 15% per year.Buy Or Sell Opportunity • Feb 19Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 10% to zł19.70. The fair value is estimated to be zł24.82, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 13%.공시 • Nov 12Biogened S.A. to Report Q3, 2025 Results on Nov 14, 2025Biogened S.A. announced that they will report Q3, 2025 results on Nov 14, 2025더 많은 업데이트 보기Recent updatesBuy Or Sell Opportunity • Apr 20Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 6.6% to zł19.80. The fair value is estimated to be zł24.82, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 13%.New Risk • Apr 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Market cap is less than US$100m (zł60.9m market cap, or US$17.0m).Valuation Update With 7 Day Price Move • Apr 15Investor sentiment improves as stock rises 39%After last week's 39% share price gain to zł24.80, the stock trades at a trailing P/E ratio of 13.2x. Average trailing P/E is 22x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 96% over the past three years.Reported Earnings • Feb 19Full year 2025 earnings released: EPS: zł1.88 (vs zł2.37 in FY 2024)Full year 2025 results: EPS: zł1.88 (down from zł2.37 in FY 2024). Revenue: zł114.0m (up 2.8% from FY 2024). Net income: zł4.62m (down 21% from FY 2024). Profit margin: 4.1% (down from 5.2% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 15% per year.Buy Or Sell Opportunity • Feb 19Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 10% to zł19.70. The fair value is estimated to be zł24.82, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 13%.공시 • Nov 12Biogened S.A. to Report Q3, 2025 Results on Nov 14, 2025Biogened S.A. announced that they will report Q3, 2025 results on Nov 14, 2025분석 기사 • Sep 09Biogened (WSE:BGD) Will Pay A Dividend Of PLN0.50The board of Biogened S.A. ( WSE:BGD ) has announced that it will pay a dividend of PLN0.50 per share on the 17th of...Upcoming Dividend • Sep 04Upcoming dividend of zł0.50 per shareEligible shareholders must have bought the stock before 11 September 2025. Payment date: 17 November 2025. Payout ratio is a comfortable 25% but the company is paying out more than the cash it is generating. Trailing yield: 2.0%. Lower than top quartile of Polish dividend payers (7.3%). Lower than average of industry peers (2.8%).분석 기사 • Aug 23Biogened's (WSE:BGD) Promising Earnings May Rest On Soft FoundationsBiogened S.A. ( WSE:BGD ) just reported some strong earnings, and the market reacted accordingly with a healthy uplift...New Risk • Aug 22New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 17% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risk Market cap is less than US$100m (zł59.4m market cap, or US$16.2m).분석 기사 • Aug 15Market Participants Recognise Biogened S.A.'s (WSE:BGD) EarningsThere wouldn't be many who think Biogened S.A.'s ( WSE:BGD ) price-to-earnings (or "P/E") ratio of 14.4x is worth a...Valuation Update With 7 Day Price Move • Jul 22Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to zł25.20, the stock trades at a trailing P/E ratio of 13x. Average trailing P/E is 22x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 105% over the past three years.분석 기사 • Jul 11Biogened (WSE:BGD) Has A Pretty Healthy Balance SheetDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Valuation Update With 7 Day Price Move • Jul 07Investor sentiment improves as stock rises 32%After last week's 32% share price gain to zł32.00, the stock trades at a trailing P/E ratio of 16.4x. Average trailing P/E is 21x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 173% over the past three years.Valuation Update With 7 Day Price Move • Jun 09Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to zł26.80, the stock trades at a trailing P/E ratio of 13.8x. Average trailing P/E is 22x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 104% over the past three years.Declared Dividend • Jun 05Dividend of zł0.50 announcedDividend of zł0.50 is the same as last year. Ex-date: 11th September 2025 Payment date: 17th November 2025 Dividend yield will be 1.9%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is well covered by both earnings (25% earnings payout ratio) and cash flows (30% cash payout ratio). The dividend has increased by an average of 26% per year over the past 4 years and payments have been stable during that time. Earnings per share has grown by 27% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.공시 • Jun 04Biogened S.A. announces Annual dividend, payable on November 17, 2025Biogened S.A. announced Annual dividend of PLN 0.5000 per share payable on November 17, 2025, ex-date on September 11, 2025 and record date on September 12, 2025.Reported Earnings • May 19First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: zł32.9m (up 11% from 1Q 2024). Net income: zł2.31m (up 10.0% from 1Q 2024). Profit margin: 7.0% (in line with 1Q 2024).분석 기사 • May 01Investors Interested In Biogened S.A.'s (WSE:BGD) EarningsWith a price-to-earnings (or "P/E") ratio of 17.1x Biogened S.A. ( WSE:BGD ) may be sending bearish signals at the...Valuation Update With 7 Day Price Move • Apr 30Investor sentiment improves as stock rises 19%After last week's 19% share price gain to zł31.80, the stock trades at a trailing P/E ratio of 17.1x. Average trailing P/E is 22x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 217% over the past three years.Reported Earnings • Feb 19Full year 2024 earnings released: EPS: zł1.86 (vs zł2.08 in FY 2023)Full year 2024 results: EPS: zł1.86 (down from zł2.08 in FY 2023). Revenue: zł110.9m (up 16% from FY 2023). Net income: zł4.57m (down 10% from FY 2023). Profit margin: 4.1% (down from 5.3% in FY 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 21% per year whereas the company’s share price has increased by 26% per year.Valuation Update With 7 Day Price Move • Feb 18Investor sentiment deteriorates as stock falls 25%After last week's 25% share price decline to zł22.40, the stock trades at a trailing P/E ratio of 11.3x. Average trailing P/E is 23x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 113% over the past three years.Valuation Update With 7 Day Price Move • Feb 01Investor sentiment improves as stock rises 19%After last week's 19% share price gain to zł31.00, the stock trades at a trailing P/E ratio of 15.6x. Average trailing P/E is 22x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 206% over the past three years.분석 기사 • Jan 20Investors Appear Satisfied With Biogened S.A.'s (WSE:BGD) Prospects As Shares Rocket 44%Biogened S.A. ( WSE:BGD ) shareholders would be excited to see that the share price has had a great month, posting a...Valuation Update With 7 Day Price Move • Jan 17Investor sentiment improves as stock rises 20%After last week's 20% share price gain to zł28.80, the stock trades at a trailing P/E ratio of 14.5x. Average trailing P/E is 20x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 193% over the past three years.분석 기사 • Dec 06Investors Give Biogened S.A. (WSE:BGD) Shares A 27% HidingThe Biogened S.A. ( WSE:BGD ) share price has fared very poorly over the last month, falling by a substantial 27...Valuation Update With 7 Day Price Move • Nov 28Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to zł19.40, the stock trades at a trailing P/E ratio of 9.8x. Average trailing P/E is 20x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 137% over the past three years.Reported Earnings • Nov 19Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: zł21.4m (up 7.3% from 3Q 2023). Net income: zł104.5k (down 82% from 3Q 2023). Profit margin: 0.5% (down from 3.0% in 3Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.New Risk • Nov 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 8.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.9% average weekly change). Minor Risks High level of debt (41% net debt to equity). Market cap is less than US$100m (zł55.0m market cap, or US$13.4m).분석 기사 • Nov 06Biogened (WSE:BGD) Takes On Some Risk With Its Use Of DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...분석 기사 • Aug 28A Piece Of The Puzzle Missing From Biogened S.A.'s (WSE:BGD) 25% Share Price ClimbDespite an already strong run, Biogened S.A. ( WSE:BGD ) shares have been powering on, with a gain of 25% in the last...분석 기사 • Aug 22Impressive Earnings May Not Tell The Whole Story For Biogened (WSE:BGD)Last week's profit announcement from Biogened S.A. ( WSE:BGD ) was underwhelming for investors, despite headline...Reported Earnings • Aug 18Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: zł30.7m (up 25% from 2Q 2023). Net income: zł1.63m (up 2.4% from 2Q 2023). Profit margin: 5.3% (down from 6.5% in 2Q 2023). The decrease in margin was driven by higher expenses.Valuation Update With 7 Day Price Move • Jun 05Investor sentiment improves as stock rises 15%After last week's 15% share price gain to zł20.60, the stock trades at a trailing P/E ratio of 11.4x. Average trailing P/E is 25x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 75% over the past three years.공시 • Jun 05Biogened S.A., Annual General Meeting, Jun 28, 2024Biogened S.A., Annual General Meeting, Jun 28, 2024.분석 기사 • May 23Investors Give Biogened S.A. (WSE:BGD) Shares A 37% HidingThe Biogened S.A. ( WSE:BGD ) share price has fared very poorly over the last month, falling by a substantial 37...Valuation Update With 7 Day Price Move • May 22Investor sentiment deteriorates as stock falls 30%After last week's 30% share price decline to zł16.20, the stock trades at a trailing P/E ratio of 9x. Average trailing P/E is 25x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 59% over the past three years.Reported Earnings • May 19First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: zł29.6m (up 16% from 1Q 2023). Net income: zł2.10m (up 12% from 1Q 2023). Profit margin: 7.1% (down from 7.4% in 1Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth.분석 기사 • May 09Here's Why Biogened (WSE:BGD) Has A Meaningful Debt BurdenThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Valuation Update With 7 Day Price Move • Mar 15Investor sentiment improves as stock rises 17%After last week's 17% share price gain to zł30.40, the stock trades at a trailing P/E ratio of 17.8x. Average trailing P/E is 24x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 178% over the past three years.분석 기사 • Feb 21Biogened's (WSE:BGD) Promising Earnings May Rest On Soft FoundationsBiogened S.A. ( WSE:BGD ) announced strong profits, but the stock was stagnant. Our analysis suggests that shareholders...Reported Earnings • Feb 16Full year 2023 earnings released: EPS: zł1.71 (vs zł1.38 in FY 2022)Full year 2023 results: EPS: zł1.71 (up from zł1.38 in FY 2022). Revenue: zł95.6m (up 20% from FY 2022). Net income: zł4.20m (up 24% from FY 2022). Profit margin: 4.4% (up from 4.2% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.공시 • Feb 02+ 4 more updatesBiogened S.A. to Report Q3, 2024 Results on Nov 14, 2024Biogened S.A. announced that they will report Q3, 2024 results on Nov 14, 2024분석 기사 • Feb 01Is Biogened (WSE:BGD) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Feb 01Biogened S.A. (WSE:BGD) Looks Just Right With A 37% Price JumpDespite an already strong run, Biogened S.A. ( WSE:BGD ) shares have been powering on, with a gain of 37% in the last...Valuation Update With 7 Day Price Move • Jan 31Investor sentiment improves as stock rises 25%After last week's 25% share price gain to zł24.60, the stock trades at a trailing P/E ratio of 16x. Average trailing P/E is 24x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 144% over the past three years.Upcoming Dividend • Sep 05Upcoming dividend of zł0.40 per share at 2.6% yieldEligible shareholders must have bought the stock before 12 September 2023. Payment date: 17 November 2023. Payout ratio is a comfortable 28% but the company is not cash flow positive. Trailing yield: 2.6%. Lower than top quartile of Polish dividend payers (7.6%). In line with average of industry peers (2.6%).Reported Earnings • Aug 16Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: zł24.5m (up 22% from 2Q 2022). Net income: zł1.59m (down 1.7% from 2Q 2022). Profit margin: 6.5% (down from 8.1% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Jul 04Investor sentiment improves as stock rises 21%After last week's 21% share price gain to zł17.00, the stock trades at a trailing P/E ratio of 12.3x. Average trailing P/E is 20x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 33% over the past three years.분석 기사 • Jun 30We Think Biogened (WSE:BGD) Can Stay On Top Of Its DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...공시 • Jun 04Biogened S.A., Annual General Meeting, Jun 27, 2023Biogened S.A., Annual General Meeting, Jun 27, 2023, at 10:00 Central European Standard Time.Reported Earnings • May 21First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: zł25.5m (up 27% from 1Q 2022). Net income: zł1.88m (up 8.6% from 1Q 2022). Profit margin: 7.4% (down from 8.6% in 1Q 2022). The decrease in margin was driven by higher expenses.Reported Earnings • Feb 18Full year 2022 earnings released: EPS: zł1.55 (vs zł0.80 in FY 2021)Full year 2022 results: EPS: zł1.55 (up from zł0.80 in FY 2021). Revenue: zł79.6m (up 22% from FY 2021). Net income: zł3.80m (up 94% from FY 2021). Profit margin: 4.8% (up from 3.0% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.공시 • Feb 03+ 4 more updatesBiogened S.A. to Report Q3, 2023 Results on Nov 14, 2023Biogened S.A. announced that they will report Q3, 2023 results on Nov 14, 2023분석 기사 • Oct 08Biogened (WSE:BGD) Seems To Use Debt Quite SensiblyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Upcoming Dividend • Sep 05Upcoming dividend of zł0.30 per shareEligible shareholders must have bought the stock before 12 September 2022. Payment date: 18 November 2022. Payout ratio is a comfortable 13% but the company is paying out more than the cash it is generating. Trailing yield: 1.3%. Lower than top quartile of Polish dividend payers (9.3%). Lower than average of industry peers (2.8%).Reported Earnings • Aug 16Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: zł20.1m (up 9.9% from 2Q 2021). Net income: zł1.62m (up 121% from 2Q 2021). Profit margin: 8.1% (up from 4.0% in 2Q 2021). The increase in margin was driven by higher revenue.분석 기사 • Jun 29Is Biogened (WSE:BGD) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Valuation Update With 7 Day Price Move • Jun 28Investor sentiment improved over the past weekAfter last week's 24% share price gain to zł14.90, the stock trades at a trailing P/E ratio of 12.4x. Average trailing P/E is 19x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 93% over the past three years.Valuation Update With 7 Day Price Move • Jun 03Investor sentiment improved over the past weekAfter last week's 15% share price gain to zł14.50, the stock trades at a trailing P/E ratio of 12x. Average trailing P/E is 19x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 65% over the past three years.공시 • Jun 01Biogened S.A., Annual General Meeting, Jun 30, 2022Biogened S.A., Annual General Meeting, Jun 30, 2022, at 10:00 Central Europe Standard Time. Agenda: To election the Chairman of the General Meeting; To prepare and check the attendance list; To confirm that the General Meeting has been properly convened and is capable of adopting resolutions; To adopt resolution on waiving the secrecy of voting on the election of the Returning Committee; To elect the Returning Committee; To adopt agenda of the General Meeting; To adopt resolution on the approval of the Management Board's report on operations in the period from January 1, 2021 to December 31, 2021.Reported Earnings • May 19First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: zł20.0m (up 34% from 1Q 2021). Net income: zł1.73m (up 88% from 1Q 2021). Profit margin: 8.6% (up from 6.1% in 1Q 2021). The increase in margin was driven by higher revenue.분석 기사 • Mar 25Does Biogened (WSE:BGD) Have A Healthy Balance Sheet?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • Feb 17Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: zł0.88 (up from zł0.51 in FY 2020). Revenue: zł65.3m (up 35% from FY 2020). Net income: zł2.15m (up 73% from FY 2020). Profit margin: 3.3% (up from 2.6% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 17% per year whereas the company’s share price has increased by 21% per year.공시 • Feb 02+ 4 more updatesBiogened S.A. to Report Q1, 2022 Results on May 13, 2022Biogened S.A. announced that they will report Q1, 2022 results on May 13, 2022Valuation Update With 7 Day Price Move • Jan 03Investor sentiment improved over the past weekAfter last week's 20% share price gain to zł9.60, the stock trades at a trailing P/E ratio of 14.6x. Average trailing P/E is 28x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 6.6% over the past three years.분석 기사 • Dec 09These 4 Measures Indicate That Biogened (WSE:BGD) Is Using Debt Reasonably WellSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Reported Earnings • Nov 15Third quarter 2021 earnings releasedThe company reported a mediocre third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: zł13.4m (up 34% from 3Q 2020). Net income: zł59.4k (down 81% from 3Q 2020). Profit margin: 0.4% (down from 3.1% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.Upcoming Dividend • Sep 03Upcoming dividend of zł0.20 per shareEligible shareholders must have bought the stock before 10 September 2021. Payment date: 18 November 2021. Trailing yield: 2.3%. Lower than top quartile of Polish dividend payers (5.8%). Lower than average of industry peers (2.6%).Reported Earnings • Aug 19Second quarter 2021 earnings releasedThe company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: zł18.3m (up 30% from 2Q 2020). Net income: zł734.2k (up 210% from 2Q 2020). Profit margin: 4.0% (up from 1.7% in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Aug 10Investor sentiment improved over the past weekAfter last week's 24% share price gain to zł8.65, the stock trades at a trailing P/E ratio of 15.5x. Average trailing P/E is 26x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 34% over the past three years.분석 기사 • Jul 29Biogened (WSE:BGD) Has A Somewhat Strained Balance SheetLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Valuation Update With 7 Day Price Move • Jul 23Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to zł9.70, the stock trades at a trailing P/E ratio of 17.3x. Average trailing P/E is 26x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 34% over the past three years.분석 기사 • Apr 30Biogened (WSE:BGD) Seems To Use Debt Quite SensiblyLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • Feb 14Full year 2020 earnings released: EPS zł0.56 (vs zł0.49 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: zł48.3m (up 3.6% from FY 2019). Net income: zł1.37m (up 13% from FY 2019). Profit margin: 2.8% (up from 2.6% in FY 2019). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Is New 90 Day High Low • Feb 12New 90-day high: zł13.50The company is up 35% from its price of zł10.00 on 13 November 2020. The Polish market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 1.0% over the same period.Valuation Update With 7 Day Price Move • Feb 12Investor sentiment improved over the past weekAfter last week's 32% share price gain to zł13.50, the stock is trading at a trailing P/E ratio of 22.2x, up from the previous P/E ratio of 16.8x. This compares to an average P/E of 25x in the Pharmaceuticals industry in Europe. Total returns to shareholders over the past three years are 3.0%.공시 • Feb 02+ 1 more updateBiogened S.A. to Report Q1, 2021 Results on May 14, 2021Biogened S.A. announced that they will report Q1, 2021 results on May 14, 2021공시 • Feb 01+ 2 more updatesBiogened S.A. to Report Q3, 2021 Results on Nov 12, 2021Biogened S.A. announced that they will report Q3, 2021 results on Nov 12, 2021분석 기사 • Jan 24Is Biogened (WSE:BGD) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Valuation Update With 7 Day Price Move • Jan 18Investor sentiment improved over the past weekAfter last week's 17% share price gain to zł10.50, the stock is trading at a trailing P/E ratio of 17.3x, up from the previous P/E ratio of 14.8x. This compares to an average P/E of 23x in the Pharmaceuticals industry in Europe. Total return to shareholders over the past three years is a loss of 8.1%.Valuation Update With 7 Day Price Move • Jan 14Investor sentiment improved over the past weekAfter last week's 17% share price gain to zł10.20, the stock is trading at a trailing P/E ratio of 16.8x, up from the previous P/E ratio of 14.3x. This compares to an average P/E of 23x in the Pharmaceuticals industry in Europe. Total return to shareholders over the past three years is a loss of 12%.Valuation Update With 7 Day Price Move • Dec 08Market pulls back on stock over the past weekAfter last week's 18% share price decline to zł8.10, the stock is trading at a trailing P/E ratio of 13.3x, down from the previous P/E ratio of 16.3x. This compares to an average P/E of 23x in the Pharmaceuticals industry in Europe. Total return to shareholders over the past three years is a loss of 35%.주주 수익률BGDPL PharmaceuticalsPL 시장7D-4.6%-0.09%2.5%1Y-39.2%-13.3%28.2%전체 주주 수익률 보기수익률 대 산업: BGD은 지난 1년 동안 -13.3%의 수익을 기록한 Polish Pharmaceuticals 산업보다 저조한 성과를 냈습니다.수익률 대 시장: BGD은 지난 1년 동안 28.2%를 기록한 Polish 시장보다 저조한 성과를 냈습니다.주가 변동성Is BGD's price volatile compared to industry and market?BGD volatilityBGD Average Weekly Movement15.5%Pharmaceuticals Industry Average Movement6.0%Market Average Movement5.3%10% most volatile stocks in PL Market10.9%10% least volatile stocks in PL Market3.1%안정적인 주가: BGD의 주가는 지난 3개월 동안 Polish 시장보다 변동성이 컸습니다.시간에 따른 변동성: BGD의 주간 변동성(16%)은 지난 1년 동안 안정적이었지만 Polish 종목 중 상위 75%보다 높습니다.회사 소개설립직원 수CEO웹사이트2007195Andrzej Grzegorzewskiwww.biogened.pl바이오젠은 폴란드에서 의약품을 개발, 생산 및 유통하는 회사입니다. 이 회사는 더메딕 브랜드로 더모 코스메틱과 온천수를 제공합니다. 또한 제품을 수출하고 있습니다.더 보기Biogened S.A. 기초 지표 요약Biogened의 순이익과 매출은 시가총액과 어떻게 비교됩니까?BGD 기초 통계시가총액zł45.69m순이익 (TTM)zł4.62m매출 (TTM)zł114.04m9.9x주가수익비율(P/E)0.4x주가매출비율(P/S)BGD는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표BGD 손익계산서 (TTM)매출zł114.04m매출원가zł41.00m총이익zł73.04m기타 비용zł68.42m순이익zł4.62m최근 보고된 실적Dec 31, 2025다음 실적 발표일May 29, 2026주당순이익(EPS)1.88총이익률64.05%순이익률4.05%부채/자본 비율47.0%BGD의 장기 실적은 어땠습니까?과거 실적 및 비교 보기배당2.7%현재 배당 수익률21%배당 성향View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 15:58종가2026/05/22 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Biogened S.A.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Buy Or Sell Opportunity • Apr 20Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 6.6% to zł19.80. The fair value is estimated to be zł24.82, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 13%.
New Risk • Apr 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Market cap is less than US$100m (zł60.9m market cap, or US$17.0m).
Valuation Update With 7 Day Price Move • Apr 15Investor sentiment improves as stock rises 39%After last week's 39% share price gain to zł24.80, the stock trades at a trailing P/E ratio of 13.2x. Average trailing P/E is 22x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 96% over the past three years.
Reported Earnings • Feb 19Full year 2025 earnings released: EPS: zł1.88 (vs zł2.37 in FY 2024)Full year 2025 results: EPS: zł1.88 (down from zł2.37 in FY 2024). Revenue: zł114.0m (up 2.8% from FY 2024). Net income: zł4.62m (down 21% from FY 2024). Profit margin: 4.1% (down from 5.2% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 15% per year.
Buy Or Sell Opportunity • Feb 19Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 10% to zł19.70. The fair value is estimated to be zł24.82, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 13%.
공시 • Nov 12Biogened S.A. to Report Q3, 2025 Results on Nov 14, 2025Biogened S.A. announced that they will report Q3, 2025 results on Nov 14, 2025
Buy Or Sell Opportunity • Apr 20Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 6.6% to zł19.80. The fair value is estimated to be zł24.82, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 13%.
New Risk • Apr 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Market cap is less than US$100m (zł60.9m market cap, or US$17.0m).
Valuation Update With 7 Day Price Move • Apr 15Investor sentiment improves as stock rises 39%After last week's 39% share price gain to zł24.80, the stock trades at a trailing P/E ratio of 13.2x. Average trailing P/E is 22x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 96% over the past three years.
Reported Earnings • Feb 19Full year 2025 earnings released: EPS: zł1.88 (vs zł2.37 in FY 2024)Full year 2025 results: EPS: zł1.88 (down from zł2.37 in FY 2024). Revenue: zł114.0m (up 2.8% from FY 2024). Net income: zł4.62m (down 21% from FY 2024). Profit margin: 4.1% (down from 5.2% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 15% per year.
Buy Or Sell Opportunity • Feb 19Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 10% to zł19.70. The fair value is estimated to be zł24.82, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 13%.
공시 • Nov 12Biogened S.A. to Report Q3, 2025 Results on Nov 14, 2025Biogened S.A. announced that they will report Q3, 2025 results on Nov 14, 2025
분석 기사 • Sep 09Biogened (WSE:BGD) Will Pay A Dividend Of PLN0.50The board of Biogened S.A. ( WSE:BGD ) has announced that it will pay a dividend of PLN0.50 per share on the 17th of...
Upcoming Dividend • Sep 04Upcoming dividend of zł0.50 per shareEligible shareholders must have bought the stock before 11 September 2025. Payment date: 17 November 2025. Payout ratio is a comfortable 25% but the company is paying out more than the cash it is generating. Trailing yield: 2.0%. Lower than top quartile of Polish dividend payers (7.3%). Lower than average of industry peers (2.8%).
분석 기사 • Aug 23Biogened's (WSE:BGD) Promising Earnings May Rest On Soft FoundationsBiogened S.A. ( WSE:BGD ) just reported some strong earnings, and the market reacted accordingly with a healthy uplift...
New Risk • Aug 22New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 17% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risk Market cap is less than US$100m (zł59.4m market cap, or US$16.2m).
분석 기사 • Aug 15Market Participants Recognise Biogened S.A.'s (WSE:BGD) EarningsThere wouldn't be many who think Biogened S.A.'s ( WSE:BGD ) price-to-earnings (or "P/E") ratio of 14.4x is worth a...
Valuation Update With 7 Day Price Move • Jul 22Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to zł25.20, the stock trades at a trailing P/E ratio of 13x. Average trailing P/E is 22x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 105% over the past three years.
분석 기사 • Jul 11Biogened (WSE:BGD) Has A Pretty Healthy Balance SheetDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Valuation Update With 7 Day Price Move • Jul 07Investor sentiment improves as stock rises 32%After last week's 32% share price gain to zł32.00, the stock trades at a trailing P/E ratio of 16.4x. Average trailing P/E is 21x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 173% over the past three years.
Valuation Update With 7 Day Price Move • Jun 09Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to zł26.80, the stock trades at a trailing P/E ratio of 13.8x. Average trailing P/E is 22x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 104% over the past three years.
Declared Dividend • Jun 05Dividend of zł0.50 announcedDividend of zł0.50 is the same as last year. Ex-date: 11th September 2025 Payment date: 17th November 2025 Dividend yield will be 1.9%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is well covered by both earnings (25% earnings payout ratio) and cash flows (30% cash payout ratio). The dividend has increased by an average of 26% per year over the past 4 years and payments have been stable during that time. Earnings per share has grown by 27% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
공시 • Jun 04Biogened S.A. announces Annual dividend, payable on November 17, 2025Biogened S.A. announced Annual dividend of PLN 0.5000 per share payable on November 17, 2025, ex-date on September 11, 2025 and record date on September 12, 2025.
Reported Earnings • May 19First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: zł32.9m (up 11% from 1Q 2024). Net income: zł2.31m (up 10.0% from 1Q 2024). Profit margin: 7.0% (in line with 1Q 2024).
분석 기사 • May 01Investors Interested In Biogened S.A.'s (WSE:BGD) EarningsWith a price-to-earnings (or "P/E") ratio of 17.1x Biogened S.A. ( WSE:BGD ) may be sending bearish signals at the...
Valuation Update With 7 Day Price Move • Apr 30Investor sentiment improves as stock rises 19%After last week's 19% share price gain to zł31.80, the stock trades at a trailing P/E ratio of 17.1x. Average trailing P/E is 22x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 217% over the past three years.
Reported Earnings • Feb 19Full year 2024 earnings released: EPS: zł1.86 (vs zł2.08 in FY 2023)Full year 2024 results: EPS: zł1.86 (down from zł2.08 in FY 2023). Revenue: zł110.9m (up 16% from FY 2023). Net income: zł4.57m (down 10% from FY 2023). Profit margin: 4.1% (down from 5.3% in FY 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 21% per year whereas the company’s share price has increased by 26% per year.
Valuation Update With 7 Day Price Move • Feb 18Investor sentiment deteriorates as stock falls 25%After last week's 25% share price decline to zł22.40, the stock trades at a trailing P/E ratio of 11.3x. Average trailing P/E is 23x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 113% over the past three years.
Valuation Update With 7 Day Price Move • Feb 01Investor sentiment improves as stock rises 19%After last week's 19% share price gain to zł31.00, the stock trades at a trailing P/E ratio of 15.6x. Average trailing P/E is 22x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 206% over the past three years.
분석 기사 • Jan 20Investors Appear Satisfied With Biogened S.A.'s (WSE:BGD) Prospects As Shares Rocket 44%Biogened S.A. ( WSE:BGD ) shareholders would be excited to see that the share price has had a great month, posting a...
Valuation Update With 7 Day Price Move • Jan 17Investor sentiment improves as stock rises 20%After last week's 20% share price gain to zł28.80, the stock trades at a trailing P/E ratio of 14.5x. Average trailing P/E is 20x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 193% over the past three years.
분석 기사 • Dec 06Investors Give Biogened S.A. (WSE:BGD) Shares A 27% HidingThe Biogened S.A. ( WSE:BGD ) share price has fared very poorly over the last month, falling by a substantial 27...
Valuation Update With 7 Day Price Move • Nov 28Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to zł19.40, the stock trades at a trailing P/E ratio of 9.8x. Average trailing P/E is 20x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 137% over the past three years.
Reported Earnings • Nov 19Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: zł21.4m (up 7.3% from 3Q 2023). Net income: zł104.5k (down 82% from 3Q 2023). Profit margin: 0.5% (down from 3.0% in 3Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.
New Risk • Nov 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 8.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.9% average weekly change). Minor Risks High level of debt (41% net debt to equity). Market cap is less than US$100m (zł55.0m market cap, or US$13.4m).
분석 기사 • Nov 06Biogened (WSE:BGD) Takes On Some Risk With Its Use Of DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
분석 기사 • Aug 28A Piece Of The Puzzle Missing From Biogened S.A.'s (WSE:BGD) 25% Share Price ClimbDespite an already strong run, Biogened S.A. ( WSE:BGD ) shares have been powering on, with a gain of 25% in the last...
분석 기사 • Aug 22Impressive Earnings May Not Tell The Whole Story For Biogened (WSE:BGD)Last week's profit announcement from Biogened S.A. ( WSE:BGD ) was underwhelming for investors, despite headline...
Reported Earnings • Aug 18Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: zł30.7m (up 25% from 2Q 2023). Net income: zł1.63m (up 2.4% from 2Q 2023). Profit margin: 5.3% (down from 6.5% in 2Q 2023). The decrease in margin was driven by higher expenses.
Valuation Update With 7 Day Price Move • Jun 05Investor sentiment improves as stock rises 15%After last week's 15% share price gain to zł20.60, the stock trades at a trailing P/E ratio of 11.4x. Average trailing P/E is 25x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 75% over the past three years.
공시 • Jun 05Biogened S.A., Annual General Meeting, Jun 28, 2024Biogened S.A., Annual General Meeting, Jun 28, 2024.
분석 기사 • May 23Investors Give Biogened S.A. (WSE:BGD) Shares A 37% HidingThe Biogened S.A. ( WSE:BGD ) share price has fared very poorly over the last month, falling by a substantial 37...
Valuation Update With 7 Day Price Move • May 22Investor sentiment deteriorates as stock falls 30%After last week's 30% share price decline to zł16.20, the stock trades at a trailing P/E ratio of 9x. Average trailing P/E is 25x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 59% over the past three years.
Reported Earnings • May 19First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: zł29.6m (up 16% from 1Q 2023). Net income: zł2.10m (up 12% from 1Q 2023). Profit margin: 7.1% (down from 7.4% in 1Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth.
분석 기사 • May 09Here's Why Biogened (WSE:BGD) Has A Meaningful Debt BurdenThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Valuation Update With 7 Day Price Move • Mar 15Investor sentiment improves as stock rises 17%After last week's 17% share price gain to zł30.40, the stock trades at a trailing P/E ratio of 17.8x. Average trailing P/E is 24x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 178% over the past three years.
분석 기사 • Feb 21Biogened's (WSE:BGD) Promising Earnings May Rest On Soft FoundationsBiogened S.A. ( WSE:BGD ) announced strong profits, but the stock was stagnant. Our analysis suggests that shareholders...
Reported Earnings • Feb 16Full year 2023 earnings released: EPS: zł1.71 (vs zł1.38 in FY 2022)Full year 2023 results: EPS: zł1.71 (up from zł1.38 in FY 2022). Revenue: zł95.6m (up 20% from FY 2022). Net income: zł4.20m (up 24% from FY 2022). Profit margin: 4.4% (up from 4.2% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.
공시 • Feb 02+ 4 more updatesBiogened S.A. to Report Q3, 2024 Results on Nov 14, 2024Biogened S.A. announced that they will report Q3, 2024 results on Nov 14, 2024
분석 기사 • Feb 01Is Biogened (WSE:BGD) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
분석 기사 • Feb 01Biogened S.A. (WSE:BGD) Looks Just Right With A 37% Price JumpDespite an already strong run, Biogened S.A. ( WSE:BGD ) shares have been powering on, with a gain of 37% in the last...
Valuation Update With 7 Day Price Move • Jan 31Investor sentiment improves as stock rises 25%After last week's 25% share price gain to zł24.60, the stock trades at a trailing P/E ratio of 16x. Average trailing P/E is 24x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 144% over the past three years.
Upcoming Dividend • Sep 05Upcoming dividend of zł0.40 per share at 2.6% yieldEligible shareholders must have bought the stock before 12 September 2023. Payment date: 17 November 2023. Payout ratio is a comfortable 28% but the company is not cash flow positive. Trailing yield: 2.6%. Lower than top quartile of Polish dividend payers (7.6%). In line with average of industry peers (2.6%).
Reported Earnings • Aug 16Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: zł24.5m (up 22% from 2Q 2022). Net income: zł1.59m (down 1.7% from 2Q 2022). Profit margin: 6.5% (down from 8.1% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Jul 04Investor sentiment improves as stock rises 21%After last week's 21% share price gain to zł17.00, the stock trades at a trailing P/E ratio of 12.3x. Average trailing P/E is 20x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 33% over the past three years.
분석 기사 • Jun 30We Think Biogened (WSE:BGD) Can Stay On Top Of Its DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
공시 • Jun 04Biogened S.A., Annual General Meeting, Jun 27, 2023Biogened S.A., Annual General Meeting, Jun 27, 2023, at 10:00 Central European Standard Time.
Reported Earnings • May 21First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: zł25.5m (up 27% from 1Q 2022). Net income: zł1.88m (up 8.6% from 1Q 2022). Profit margin: 7.4% (down from 8.6% in 1Q 2022). The decrease in margin was driven by higher expenses.
Reported Earnings • Feb 18Full year 2022 earnings released: EPS: zł1.55 (vs zł0.80 in FY 2021)Full year 2022 results: EPS: zł1.55 (up from zł0.80 in FY 2021). Revenue: zł79.6m (up 22% from FY 2021). Net income: zł3.80m (up 94% from FY 2021). Profit margin: 4.8% (up from 3.0% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.
공시 • Feb 03+ 4 more updatesBiogened S.A. to Report Q3, 2023 Results on Nov 14, 2023Biogened S.A. announced that they will report Q3, 2023 results on Nov 14, 2023
분석 기사 • Oct 08Biogened (WSE:BGD) Seems To Use Debt Quite SensiblyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Upcoming Dividend • Sep 05Upcoming dividend of zł0.30 per shareEligible shareholders must have bought the stock before 12 September 2022. Payment date: 18 November 2022. Payout ratio is a comfortable 13% but the company is paying out more than the cash it is generating. Trailing yield: 1.3%. Lower than top quartile of Polish dividend payers (9.3%). Lower than average of industry peers (2.8%).
Reported Earnings • Aug 16Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: zł20.1m (up 9.9% from 2Q 2021). Net income: zł1.62m (up 121% from 2Q 2021). Profit margin: 8.1% (up from 4.0% in 2Q 2021). The increase in margin was driven by higher revenue.
분석 기사 • Jun 29Is Biogened (WSE:BGD) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Valuation Update With 7 Day Price Move • Jun 28Investor sentiment improved over the past weekAfter last week's 24% share price gain to zł14.90, the stock trades at a trailing P/E ratio of 12.4x. Average trailing P/E is 19x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 93% over the past three years.
Valuation Update With 7 Day Price Move • Jun 03Investor sentiment improved over the past weekAfter last week's 15% share price gain to zł14.50, the stock trades at a trailing P/E ratio of 12x. Average trailing P/E is 19x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 65% over the past three years.
공시 • Jun 01Biogened S.A., Annual General Meeting, Jun 30, 2022Biogened S.A., Annual General Meeting, Jun 30, 2022, at 10:00 Central Europe Standard Time. Agenda: To election the Chairman of the General Meeting; To prepare and check the attendance list; To confirm that the General Meeting has been properly convened and is capable of adopting resolutions; To adopt resolution on waiving the secrecy of voting on the election of the Returning Committee; To elect the Returning Committee; To adopt agenda of the General Meeting; To adopt resolution on the approval of the Management Board's report on operations in the period from January 1, 2021 to December 31, 2021.
Reported Earnings • May 19First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: zł20.0m (up 34% from 1Q 2021). Net income: zł1.73m (up 88% from 1Q 2021). Profit margin: 8.6% (up from 6.1% in 1Q 2021). The increase in margin was driven by higher revenue.
분석 기사 • Mar 25Does Biogened (WSE:BGD) Have A Healthy Balance Sheet?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • Feb 17Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: zł0.88 (up from zł0.51 in FY 2020). Revenue: zł65.3m (up 35% from FY 2020). Net income: zł2.15m (up 73% from FY 2020). Profit margin: 3.3% (up from 2.6% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 17% per year whereas the company’s share price has increased by 21% per year.
공시 • Feb 02+ 4 more updatesBiogened S.A. to Report Q1, 2022 Results on May 13, 2022Biogened S.A. announced that they will report Q1, 2022 results on May 13, 2022
Valuation Update With 7 Day Price Move • Jan 03Investor sentiment improved over the past weekAfter last week's 20% share price gain to zł9.60, the stock trades at a trailing P/E ratio of 14.6x. Average trailing P/E is 28x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 6.6% over the past three years.
분석 기사 • Dec 09These 4 Measures Indicate That Biogened (WSE:BGD) Is Using Debt Reasonably WellSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Reported Earnings • Nov 15Third quarter 2021 earnings releasedThe company reported a mediocre third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: zł13.4m (up 34% from 3Q 2020). Net income: zł59.4k (down 81% from 3Q 2020). Profit margin: 0.4% (down from 3.1% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
Upcoming Dividend • Sep 03Upcoming dividend of zł0.20 per shareEligible shareholders must have bought the stock before 10 September 2021. Payment date: 18 November 2021. Trailing yield: 2.3%. Lower than top quartile of Polish dividend payers (5.8%). Lower than average of industry peers (2.6%).
Reported Earnings • Aug 19Second quarter 2021 earnings releasedThe company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: zł18.3m (up 30% from 2Q 2020). Net income: zł734.2k (up 210% from 2Q 2020). Profit margin: 4.0% (up from 1.7% in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Aug 10Investor sentiment improved over the past weekAfter last week's 24% share price gain to zł8.65, the stock trades at a trailing P/E ratio of 15.5x. Average trailing P/E is 26x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 34% over the past three years.
분석 기사 • Jul 29Biogened (WSE:BGD) Has A Somewhat Strained Balance SheetLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Valuation Update With 7 Day Price Move • Jul 23Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to zł9.70, the stock trades at a trailing P/E ratio of 17.3x. Average trailing P/E is 26x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 34% over the past three years.
분석 기사 • Apr 30Biogened (WSE:BGD) Seems To Use Debt Quite SensiblyLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • Feb 14Full year 2020 earnings released: EPS zł0.56 (vs zł0.49 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: zł48.3m (up 3.6% from FY 2019). Net income: zł1.37m (up 13% from FY 2019). Profit margin: 2.8% (up from 2.6% in FY 2019). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Is New 90 Day High Low • Feb 12New 90-day high: zł13.50The company is up 35% from its price of zł10.00 on 13 November 2020. The Polish market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 1.0% over the same period.
Valuation Update With 7 Day Price Move • Feb 12Investor sentiment improved over the past weekAfter last week's 32% share price gain to zł13.50, the stock is trading at a trailing P/E ratio of 22.2x, up from the previous P/E ratio of 16.8x. This compares to an average P/E of 25x in the Pharmaceuticals industry in Europe. Total returns to shareholders over the past three years are 3.0%.
공시 • Feb 02+ 1 more updateBiogened S.A. to Report Q1, 2021 Results on May 14, 2021Biogened S.A. announced that they will report Q1, 2021 results on May 14, 2021
공시 • Feb 01+ 2 more updatesBiogened S.A. to Report Q3, 2021 Results on Nov 12, 2021Biogened S.A. announced that they will report Q3, 2021 results on Nov 12, 2021
분석 기사 • Jan 24Is Biogened (WSE:BGD) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Valuation Update With 7 Day Price Move • Jan 18Investor sentiment improved over the past weekAfter last week's 17% share price gain to zł10.50, the stock is trading at a trailing P/E ratio of 17.3x, up from the previous P/E ratio of 14.8x. This compares to an average P/E of 23x in the Pharmaceuticals industry in Europe. Total return to shareholders over the past three years is a loss of 8.1%.
Valuation Update With 7 Day Price Move • Jan 14Investor sentiment improved over the past weekAfter last week's 17% share price gain to zł10.20, the stock is trading at a trailing P/E ratio of 16.8x, up from the previous P/E ratio of 14.3x. This compares to an average P/E of 23x in the Pharmaceuticals industry in Europe. Total return to shareholders over the past three years is a loss of 12%.
Valuation Update With 7 Day Price Move • Dec 08Market pulls back on stock over the past weekAfter last week's 18% share price decline to zł8.10, the stock is trading at a trailing P/E ratio of 13.3x, down from the previous P/E ratio of 16.3x. This compares to an average P/E of 23x in the Pharmaceuticals industry in Europe. Total return to shareholders over the past three years is a loss of 35%.
